Maharashtra, Delhi, amongst five states to receive the first batch of COVID-19 drug

Hetero Drug Limited, which is one of India’s leading pharmaceutical companies, has the approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir. The company has sent 20,000 vials to five states which include Maharashtra and Delhi.

Both Maharashtra and Delhi happen to be the worst affected states when it comes to the coronavirus. Gujarat and Tamil Nadu are the other two states that will receive the first batch of the drug. The drug Remdesivir is being marketed under the brand name COVIFOR in India.

The capital of Hyderabad, Telangana, where the company is based, will also receive the first batch of the drug. The next batch of the drug is to be shipped to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Kochi, Trivandrum and Goa.

According to the pharmaceutical company, a 100-milligram vial of the drug will cost ₹5,400. The recommended dose for both adults and the paediatric patients are said to be 200 mg on day one followed by a maintenance dose of 100 mg for five days.

At the moment, the drug is being manufactured at the company’s formulation facility in Hyderabad. The active pharmaceutical ingredient (API) is being made in the firm’s Visakhapatnam facility, as per reports by a news agency.

The DCGI had earlier approved the generic versions made by Cipla and Hetero for emergency use in severe cases of coronavirus. The treatment was the first to show results in trials conducted on patients suffering from the disease. It has won approval for emergency use in patients from the US, South Korea and has further received full approval in Japan.

Maharashtra, which is the worst affected state in the country because of the pandemic can, therefore, use this drug to treat critically ill patients. The state currently has 1,47,738 cases of coronavirus with 70,878 cases in Mumbai only.